CC-90002, a CD47-SIRPα axis inhibitor, was administered as a single-agent therapy in patients with relapsed/refractory AML and high-risk MDS (ClinicalTrials.gov identifier: NCT02641002). This evidence concerns the gene CD47 and acute myeloid leukemia.